Company: SION
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0002036042-25-000047
Chunk: 340

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part II, Item 8
Chunk 340
---
675 General and administrative expense1,756 575 3,046 943 Total$2,840 $971 $4,934 $1,618 

As of June 30, 2025, there was $34.1 million of unrecognized stock-based compensation expense for common stock option awards that are expected to be recognized over a weighted average period of 2.9 years. The stock-based compensation expense for restricted common stock awards was de minimis and fully recognized as of June 30, 2025, when the final vesting conditions were met. 

10. Segment Information 

The following table presents segment net loss, including significant expense categories (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Research and development expenses:External research and development expenses(1)$11,291 $5,485 $21,269 $13,204 Personnel-related expenses, excluding stock-based compensation2,4941,8214,8773,508Facility and information technology allocated expenses464460904924General and administrative expenses:Personnel-related expenses, excluding stock-based compensation2,4171,2674,6492,467General corporate and facility expenses(2)1,9028763,8451,971Other segment items(3)(500)(1,357)(994)(1,675)Net loss$18,068 $8,552 $34,550 $20,399 (1)External research and development expenses consist primarily of costs paid to third-parties including contract research organizations ("CROs"), contract development and manufacturing organizations ("CDMOs"), consultants, advisors and lab-related vendors.(2)General corporate and facility expenses consists primarily of professional services fees for legal, finance, human resources, in addition to information technology expenses and rent expense, net of sublease income.(3)Other segment items consists primarily of interest income, partially offset by non-cash expenses, such as stock-based compensation and depreciation, and amortization of discounts and premiums on marketable securities.

F-13

11. Net Loss Per Share 

The Company excluded the following shares from the computation of diluted net loss per share attributable to common stockholders as of June 30, 2025, and 2024, because including them would have had an anti-dilutive effect: Six Months EndedJune 30,20252024Convertible Preferred Stock—27,149,206Options to purchase common